3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
2
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Breast Neoplasms
17
Ovarian Neoplasms
12
Neoplasms
8
Fallopian Tube Neoplasms
8
Triple Negative Breast Neoplasms
7
Prostatic Neoplasms
6
Pancreatic Neoplasms
6
Neoplasm Metastasis
6
Endometrial Neoplasms
4
Neuroendocrine Tumors
3
Glioma
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Recurrence
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Fanconi Anemia, Complementation Group D1
2
Cholangiocarcinoma
2
Uveal Melanoma
1
Urogenital Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
SCLC,Extensive Stage
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Platinum-sensitive Ovarian Cancer
1
Interventions
Cyclophosphamide
8
fludarabine
6
cabozantinib
5
Temozolomide
4
Doxorubicin
4
Zoledronic Acid
3
X-Rays
3
Vincristine
3
Methotrexate
3
Ifosfamide
3
Gemcitabine
3
Cisplatin
3
irinotecan sucrosofate
2
atezolizumab
2
Surgical Procedures, Operative
2
Sunitinib
2
Specimen Handling
2
Radiosurgery
2
Phantoms, Imaging
2
Mesna
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Eflornithine
2
Disulfiram
2
Biopsy
2
vactosertib
1
trilaciclib
1
trametinib
1
talazoparib
1
surufatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Osteosarcoma
×
olaparib
×
Clear all
NCT06607692
2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled